Capstone Therapeutics Corp. (NASDAQ:CAPS) Stock Short Interest Falls 95.9%

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant decrease in short interest in the month of October. As of October 30th, there was short interest totaling 28,547 shares, a decrease of 95.9% from the October 15th total of 696,378 shares. Based on an average daily trading volume, of 63,445 shares, the short-interest ratio is presently 0.4 days. Approximately 5.1% of the company’s stock are short sold.

Capstone Therapeutics Stock Performance

Shares of CAPS stock traded down $0.11 during trading hours on Thursday, reaching $1.91. The stock had a trading volume of 80,081 shares, compared to its average volume of 89,722. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.39. The firm has a 50-day simple moving average of $3.88 and a 200-day simple moving average of $10.27. The firm has a market capitalization of $1.76 million, a PE ratio of -0.02 and a beta of -1.35. Capstone Therapeutics has a twelve month low of $1.83 and a twelve month high of $34.80.

Capstone Therapeutics (NASDAQ:CAPS) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($38.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.99 by ($41.39). Capstone Therapeutics had a negative return on equity of 144.43% and a negative net margin of 36.51%. The business had revenue of $19.96 million for the quarter, compared to analyst estimates of $22.50 million.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Capstone Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has an average rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.